Arbutus Biopharma Corporation (ABUS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

6/25

Growth 1 Margin 2 Expansion 1 Platform 0 Financial 2

latest quarter score

Earnings Reports

Arbutus Biopharma (ABUS) Q3 2024: Cash Runway Extends Into Q4 2026 as HBV Functional Cure Programs Advance
November 06, 2024
Arbutus Biopharma (ABUS) Q2 2024: 40% Workforce Cut Extends Cash Runway as Phase IIb HBV Focus Intensifies
August 01, 2024
Arbutus Biopharma (ABUS) Q1 2024: Cash Runway Extends to 2026 as Combination HBV Trials Advance
May 02, 2024
Arbutus Biopharma (ABUS) Q4 2023: Cash Burn Cut 26% as Pipeline Focus Narrows to Hepatitis B Cure
February 29, 2024
6
Arbutus (ABUS) Q3 2023: 24% Workforce Cut Extends Cash Runway, Refocuses on HBV Pipeline
November 07, 2023
Arbutus Biopharma (ABUS) Q2 2023: $164M Cash Runway Extends Clinical Pipeline Progress
August 03, 2023
Arbutus Biopharma (ABUS) Q1 2023: Cash Burn Cut by $5M as Pipeline Milestones Stack Up
May 04, 2023
Arbutus Biopharma (ABUS) Q4 2022: Cash Runway Extended to Q4 2024 as Four Clinical Programs Advance
March 02, 2023

Browse all companies